FogPharma Announces $145 Million Financing to Support Ongoing Clinical Development of FOG-001 and Accelerate Helicon Peptide Portfolio
Read More
Archive for Press Releases
FogPharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Read More
Fierce Biotech Names FogPharma a “Fierce 15” Biotech Company of 2023
Read More
FogPharma Announces First Patient Dosed in Phase 1/2 Clinical Trial of First-in-class TCF-blocking β-catenin Inhibitor, FOG-001, in Advanced Solid Tumors
Read More
Mathai Mammen, M.D., Ph.D., to Join FogPharma as Chairman, President and Chief Executive Officer
Read More
FogPharma Announces $178 Million Series D Financing to Advance Pipeline of First-in-Class Helicon Polypeptide Therapeutics Targeting Major Cancer Drivers
Read More
FogPharma Announces Selection of Clinical Development Candidate Directly Targeting β-Catenin
Read More
FogPharma Expands Executive Leadership Team
Read More
FogPharma® Announces $107 Million Series C Financing to Advance Direct β-Catenin Antagonist and Universal Druggability™ Platform
Read More
FogPharma Appoints Dr. Barbara Weber to its Board of Directors
Read More